| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Malathi Kandarpa, Dan Robinson, Yi-Mi Wu, Tingting Qin, Kristen Pettit, Qing Li, Gary Luker, Maureen Sartor, Arul Chinnaiyan, Moshe Talpa. Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 30. issue 9. 2024-05-01. PMID:38386293. |
mutations in jak2, calr, and mpl are considered drivers of bcr-abl-ve mpn, including essential thrombocythemia (et), polycythemia vera (pv), prefibrotic primary myelofibrosis (prepmf), and overt myelofibrosis (mf). |
2024-05-01 |
2024-05-03 |
Not clear |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
the pharmacokinetics (pk) of methylprednisolone (mpl) exhibited tissue-specific saturable binding and reversible conversion with its metabolite, methylprednisone (mpn). |
2024-04-23 |
2024-04-26 |
rat |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
blood and 11 tissues were collected in male rats after intravenous (iv) bolus doses of 50 mg/kg mpl and 20 mg/kg mpn and upon iv infusion of mpl and mpn at 0.3, 3, and 10 mg/h/kg. |
2024-04-23 |
2024-04-26 |
rat |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
the concentrations of mpl and mpn were simultaneously measured. |
2024-04-23 |
2024-04-26 |
rat |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
both dosed and formed mpl and mpn were in rapid equilibrium or achieved steady-state rapidly in plasma and tissues. |
2024-04-23 |
2024-04-26 |
rat |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
the conversion of mpl to mpn occurred in kidney, lung, and intestine with total clearance of 429 ml/h, and the back conversion occurred in liver and kidney at 1342 ml/h. |
2024-04-23 |
2024-04-26 |
rat |
| Ruihong Yu, William J Jusk. Drug metabolism and disposition: the biological fate of chemicals. 2024-04-23. PMID:38653502. |
the irreversible elimination clearance of mpl was 789 ml/h from liver and that of mpn was 2758 ml/h with liver accounting for 44%, lung 35%, and kidney 21%. |
2024-04-23 |
2024-04-26 |
rat |
| Amanpreet Kaur, Arunkumar Venkatesan, Malathi Kandarpa, Moshe Talpaz, Malini Raghava. Lysosomal Degradation Targets Mutant Calreticulin and the Thrombopoietin Receptor in Myeloproliferative Neoplasms. Blood advances. 2024-04-19. PMID:38640435. |
compared with healthy donors, platelets from mpn patients with crt mutations display low cell surface mpl. |
2024-04-19 |
2024-04-22 |
Not clear |
| Amanpreet Kaur, Arunkumar Venkatesan, Malathi Kandarpa, Moshe Talpaz, Malini Raghava. Lysosomal Degradation Targets Mutant Calreticulin and the Thrombopoietin Receptor in Myeloproliferative Neoplasms. Blood advances. 2024-04-19. PMID:38640435. |
together, these findings indicate low surface mpl as a biomarker of mutant crt-mediated mpn and induced degradation of crtdel52 and mpl as an avenue for therapeutic intervention. |
2024-04-19 |
2024-04-22 |
Not clear |
| Zhanlong Wang, Xin Tian, Jinyu Ma, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, Enbin Liu, Yani Lin, Weiping Yuan, Kun Ru, Jie Ba. Clinical laboratory characteristics and gene mutation spectrum of Ph-negative MPN patients with atypical variants of JAK2, MPL, or CALR. Cancer medicine. vol 13. issue 7. 2024-04-15. PMID:38618943. |
clinical laboratory characteristics and gene mutation spectrum of ph-negative mpn patients with atypical variants of jak2, mpl, or calr. |
2024-04-15 |
2024-04-17 |
Not clear |
| Zhanlong Wang, Xin Tian, Jinyu Ma, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, Enbin Liu, Yani Lin, Weiping Yuan, Kun Ru, Jie Ba. Clinical laboratory characteristics and gene mutation spectrum of Ph-negative MPN patients with atypical variants of JAK2, MPL, or CALR. Cancer medicine. vol 13. issue 7. 2024-04-15. PMID:38618943. |
to evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of ph-negative mpn patients with atypical variants of jak2, mpl, or calr. |
2024-04-15 |
2024-04-17 |
Not clear |
| Kira Behrens, Maria Kauppi, Elizabeth M Viney, Andrew J Kueh, Craig D Hyland, Tracy A Willson, Liam Salleh, Carolyn A de Graaf, Jeffrey J Babon, Marco J Herold, Nicos A Nicola, Warren S Alexande. Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease. Leukemia. 2024-03-16. PMID:38491305. |
we further show that in models of myeloproliferative neoplasms (mpn), where mpl is required for pathogenesis, thrombocytosis was dependent on intact mpl-y599. |
2024-03-16 |
2024-03-19 |
mouse |
| Claire Andrews, Eibhlin Conneally, Stephen E Langabee. Molecular diagnostic criteria of myeloproliferative neoplasms. Expert review of molecular diagnostics. 2023-11-24. PMID:37999991. |
myeloproliferative neoplasms (mpn) are a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by the driver mutations jak2, calr, and mpl. |
2023-11-24 |
2023-11-28 |
Not clear |
| Frederike Kramer, Ann Mullall. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. Journal of cellular and molecular medicine. 2023-08-08. PMID:37551061. |
in mpn, mutant calreticulin translates with a novel c-terminus that leads to aberrant binding to the extracellular domain of the thrombopoietin receptor, mpl. |
2023-08-08 |
2023-08-14 |
Not clear |
| Roelof H Bekendam, Katya Ravi. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms. Frontiers in cell and developmental biology. vol 11. 2023-07-17. PMID:37457287. |
several mouse models developed to recapitulate mpn phenotype with one of the driving mutations, in jak2 (jak2v617f) or in calreticulin (calr) or myeloproliferative leukemia virus oncogene receptor (mpl), have been studied for their thrombotic phenotype. |
2023-07-17 |
2023-08-14 |
mouse |
| Daniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik, Harald Herrmann, Barbara Peter, Michael Willmann, Georg Greiner, Katharina Slavnitsch, Emir Hadzijusufovic, Thomas Rülicke, Maik Dahlhoff, Gregor Hoermann, Sigrid Machherndl-Spandl, Gregor Eisenwort, Michael Fillitz, Thamer Sliwa, Maria-Theresa Krauth, Peter Bettelheim, Wolfgang R Sperr, Elisabeth Koller, Michael Pfeilstöcker, Heinz Gisslinger, Felix Keil, Robert Kralovics, Peter Valen. Phenotypic Characterization of Disease-Initiating Stem Cells in JAK2- or CALR-mutated Myeloproliferative Neoplasms. American journal of hematology. 2023-02-23. PMID:36814396. |
myeloproliferative neoplasms (mpn) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including jak2, calr and mpl, and a substantial risk to progress to secondary acute myeloid leukemia (saml). |
2023-02-23 |
2023-08-14 |
Not clear |
| Maysam Basim Najm, Sana Dlawar Jalal, Hisham Arif Gett. The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience. Cellular and molecular biology (Noisy-le-Grand, France). vol 68. issue 8. 2023-02-21. PMID:36800830. |
considering the lack of a definitive diagnostic method in myeloproliferative disease, the results of this study showed that molecular studies, including jak2 v617f, calr, and mpl mutations and other hematological tests can be useful and effective in the diagnosis of mpn. |
2023-02-21 |
2023-08-14 |
Not clear |
| Ayalew Teffer. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology. 2023-01-21. PMID:36680511. |
primary myelofibrosis (pmf) is a myeloproliferative neoplasm (mpn) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by jak2, calr, or mpl mutations; additional features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (emh), constitutional symptoms, cachexia, risk of leukemic progression, and shortened survival. |
2023-01-21 |
2023-08-14 |
Not clear |
| Jonas S Jutzi, Anna E Marneth, María José Jiménez-Santos, Jessica Hem, Angel Guerra-Moreno, Benjamin Rolles, Shruti Bhatt, Samuel A Myers, Steven A Carr, Yuning Hong, Olga Pozdnyakova, Peter van Galen, Fátima Al-Shahrour, Anna S Nam, Ann Mullall. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response. Leukemia. 2022-12-06. PMID:36473980. |
in myeloproliferative neoplasms (mpn), somatic mutations in the calreticulin (calr) gene are disease-initiating through aberrant binding of mutant calr to the thrombopoietin receptor mpl and ligand-independent activation of jak-stat signaling. |
2022-12-06 |
2023-08-14 |
Not clear |
| Damien Luque Paz, Robert Kralovics, Radek C Skod. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2022-11-08. PMID:36347013. |
acquired gain-of-function mutations in one of three disease driver genes, jak2, calr and mpl are the causative events that can alone initiate and promote mpn disease without requiring additional cooperating mutations. |
2022-11-08 |
2023-08-14 |
Not clear |